MAP Pharmaceuticals has hired Frederick H. Graff as VP, Commercial Operations, a position newly created in anticipation of a potential launch of the company’s Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine. Graff was previously Senior VP of Sales at Sepracor, where he led the launch of Xopenex levalbuterol inhalation solution. The announcement of Mr. Graff’s hiring comes a week after the FDA accepted the company’s NDA filing for Levadex.
“We are pleased to welcome Fred to the senior management team at this pivotal time, as we build commercial infrastructure to support the launch and commercialization of LEVADEX, if approved. Fred’s accomplishments and experience with establishing and building successful sales organizations will be of great value to the Company as we pursue our goal of commercializing LEVADEX,” commented Timothy S. Nelson, President and CEO of MAP.
Read the MAP press release.
